INTRODUCTION
Novel strategies to treat pain are urgently required; more than 20% of patients do not respond to current analgesics (1, 2) . In addition, even for the responding patients, the therapeutic efficacy of opioid treatment requires improvement. Opioids, which are considered benchmark analgesics, decrease the individual pain rating by only 10 to 15% on average (3) (4) (5) . In addition, opioid treatment bears the risk of addiction and life-threatening side effects (6, 7) . These adverse effects are aggravated because patients receiving opioids quickly desensitize and therefore require ever-increasing doses. Furthermore, currently, desensitization due to the prolonged use of opioids can only be reduced but not abolished (8) .
Voltage-gated sodium channels, such as Na v 1.7, are central for the sensitivity and activation of nociceptive neurons in response to paininitiating stimuli. Although otherwise apparently normal, loss of function of Na v 1.7 results in lifelong absence of pain (congenital insensitivity to pain) in mice and humans without loss of the nociceptive neurons or their ability to fire action potentials (9) (10) (11) . The central role of Na v 1.7 in pain and its presence predominantly in nociceptive neurons make it an excellent potential target for analgesic drug development (12, 13) . Nevertheless, potent Na v 1.7 blockers fail to alleviate pain (14) .
The exact mechanisms responsible for pain insensitivity due to loss of Na v 1.7 are incompletely understood (12) . Na v 1.7 deficiency (Na v 1.7 −/− ) results in increased expression of the gene encoding the endogenous opioid met-enkephalin and increased met-enkephalin immunoreactivity in sensory neurons (15) . In addition, blocking opioid receptors with naloxone restores the ability to perceive pain in mice and humans (15) , consistent with these neurons being electrically functional yet inappropriately responsive. These data indicate that, in addition to its role in electrical signaling, Na v 1.7 is likely to have other functions that contribute to pain sensitivity. Whether the absence of Na v 1.7 only affects the abundance of endogenous opioids or whether intracellular pain signaling is also altered remains unknown.
Whereas opioid signaling is antinociceptive (inhibits pain signaling), 5-HT is pronociceptive (promotes pain signaling). In addition to increased expression of the gene encoding endogenous opioids, gene expression profiling in dorsal root ganglia of Na v 1.7-deficient mice identified reduced transcripts encoding the metabotropic serotonin (5-HT) receptor 5-HT 4 (15) , suggesting that the absence of Na v 1.7 may change not only antinociceptive but also pronociceptive signaling in sensory neurons. We investigated whether the absence of Na v 1.7 reduced 5-HT 4 receptor-mediated pronociceptive signaling, whether the opioid signaling is altered beyond the described increase of metenkephalin, and whether the changes of the pro-and antinociceptive intracellular signaling occur synergistically in the same sensory neurons.
Both Ga s -and Ga i -coupled GPCRs converge on adenylyl cyclase, such that Ga s -coupled receptors such as the 5-HT 4 receptor (16) (17) promote cAMP production and PKA signaling and Ga i -coupled receptors such as the mu opioid receptor (MOR) (18) inhibit this pathway. We used an assay for changes of cyclic adenosine monophosphate (cAMP)-induced protein kinase A (PKA) activity in untransfected primary sensory neurons (19) . Thus, with this assay, we could monitor GPCR-mediated pro-and antinociceptive signaling and the balance between these two inputs in individual neurons. To discern specific effects of the absence of Na v 1.7, we compared neurons from Na v 1.7-deficient mice with neurons from wild-type and Na v 1.8-deficient (Na v 1.8 −/− increased opioid receptor signaling. Both changes occurred synergistically in the same cells, resulting in enhanced efficacy of opioid signaling for reducing currents through the class of tetrodotoxin-resistant (TTXr) voltage-gated sodium channels, which is particularly important for action potential generation in nociceptive neurons (12) . Thus, Na v 1.7, tetrodotoxin-sensitive voltage-gated sodium channel, appears to control the homeostatic set point for pro-and antinociceptive intracellular signaling in sensory neurons.
RESULTS
The 5-HT 4 receptor is critical for the activation of PKA-II in sensory neurons from dorsal root ganglia Pronociceptive metabotropic serotonin receptors stimulate the activity of PKA; antinociceptive opioid receptors inhibit PKA activity. To test for differences in the balance of these two inputs, we first identified which Ga s -coupled metabotropic serotonin receptor, 5-HT 4 , 5-HT 6 , or 5-HT 7 , had the strongest influence on PKA signaling in individual sensory neurons, a question that has been controversial for long (17, 21, 22) . PKA signaling is activated by cAMP, resulting in dissociation of catalytic subunits from inhibitory sites such as the PKA-II regulatory subunits RIIa and RIIb (collectively referred to as pRII), which increases the relative binding of phosphorylation-specific antibodies against RII sites (19) . Inactivation of PKA-II requires degradation of cAMP by phosphodiesterases and dephosphorylation of RII subunits before reassociation of catalytic and regulatory subunits (23) . To evaluate the relative amount of PKA signaling in single neurons, we used a "high-content screening (HCS)" immunofluorescence microscopy approach to detect pRII in primary neurons isolated from dorsal root ganglia of adult male rats (19, 24) . This assay relies on signals from fluorescently tagged antibodies that distinguish neurons on the basis of the presence of the neuronal marker ubiquitin C-terminal hydrolase L1 (UCHL1) and nociceptive sensory neurons on the basis of the presence of RIIb, and quantifies the activity of cAMP-activated PKA by detecting pRII with antibodies that recognize the phosphorylated forms of both RIIa and RIIb (Fig. 1A  and fig. S1 ).
Because Na v 1.7-deficient mice had reduced transcripts encoding the metabotropic serotonin receptor 5-HT 4 (15), we tested the effect of 5-HT, the 5-HT 4 -specific agonist SC-53116 (25) , and the 5-HT 4 -specific antagonist GR113808 (26) in the cultured neurons on pRII. Both 5-HT and SC-53116 increased the intensity of the pRII signal with similar potency in rat sensory neurons (Fig. 1B) . GR113808 blocked the 5-HTinduced increase in pRII (Fig. 1C) . The 5-HT 4 agonist and antagonist results indicated that this serotonin receptor is both sufficient and necessary for 5-HT-induced increase in pRII in sensory neurons. Thus, our results suggested that the reported reduction in 5-HT 4 receptor-encoding mRNA in Na v 1.7 −/− (15) may result in a reduction of this pronociceptive signaling pathway in sensory neurons.
Opioids inhibit the 5-HT-induced PKA-II activation To examine whether the increase in production of opioids attenuated 5-HT signaling in individual sensory neurons, we used the pRII HCS microscopy assay to examine the response to opioids of neurons exposed to 5-HT. We stimulated the neurons with 5-HT, which increased the detected immune-pRII intensity, and then added increasing concentrations of opioid receptor ligands and monitored the effect on pRII signals. The clinically relevant opioid analgesic fentanyl and the MOR-specific agonist DAMGO dose-dependently inhibited the 5-HTinduced pRII signal in rat sensory neurons (Fig. 1D) , with fentanyl being the more potent of the two. Coapplication of fentanyl with 5-HT produced long-lasting inhibition of 5-HT responses at all tested doses, but fentanyl did not affect basal pRII intensity when applied alone, indicating that these neurons already had low basal adenylyl cyclase activity and thus low PKA-II activity (Fig. 1E) . The competitive opioid receptor antagonist naltrexone reversed the fentanyl-induced inhibition of pRII intensity (Fig. 1F) . Naltrexone alone had no effect on basal or 5-HT-induced pRII intensity (Fig. 1G) , indicating the absence of basal opioid receptor activity in cultured rat sensory neurons. The MOR-specific antagonist CTOP did not affect basal or 5-HT-induced pRII intensity and only partially blocked the fentanyl-induced inhibition of pRII (Fig. 1, H and I) . Coapplication of DAMGO with 5-HT also resulted in a dose-dependent, sustained inhibition of the 5-HT-induced increase in pRII (Fig. 1J) , which was fully reversed by naltrexone (Fig.  1L ) and partially by CTOP (Fig. 1L) . The ability of opioids to inhibit PKA-II activity was not limited to that stimulated by 5-HT but also extended to PKA-II activity induced by the IP 1 receptor agonist prostacyclin (PGI 2 ) or the adenylyl cyclase activator forskolin (Fsk) ( fig. S2 ).
We identified RIIb as a marker of nociceptive subgroups (19) . According to transcriptome data (27) , the gene encoding RIIb should be coexpressed with the gene encoding the opioid receptors. To demonstrate the sensitivity of RIIb(+) neurons to opioids, we analyzed the effect of fentanyl on the response to Fsk, 5-HT, or PGI 2 in RIIb(−) and RIIb(+) sensory neurons ( Fig. 2A) . After compensating for potential spillover between fluorescence channels (Fig. 2B) , we found that Fsk increased the pRII intensity in all rat sensory neurons, that is, including both RIIb(−) and RIIb(+) neurons, whereas 5-HT and PGI 2 predominantly activated RIIb(+) neurons (Fig. 2 , A, C, and D). Furthermore, we found that the inhibitory effect of fentanyl on Fsk-induced pRII was restricted to the RIIb(+) subgroup (Fig. 2 , A and C), indicating that RIIb is an indicator of sensitivity to opioids.
5-HT signaling is reduced in Na v 1.7 −/− mice With the results from wild-type rat dorsal root ganglia neurons, we could investigate whether loss of Na v 1.7 results in long-lasting changes in nociceptive neurons in addition to the reported increase in PENK expression (the gene encoding endogenous opioid precursors) in dorsal root ganglia and the processed opioid ligand met-enkephalin in the dorsal horn of the spinal cord (15) . We analyzed pRII as an indicator of functional PKA-II activation in pain-insensitive Na v 1.7 −/− mice (10). Na v 1.8
−/− mice served as a control for animals lacking a related voltage-gated Na + channel. These mice have a pain-insensitivity phenotype that is different from and less severe than that of the Na v 1.7 −/− mice (20) . We assessed general features of the cultures of dissociated dorsal root ganglia from mice of both genotypes (Fig. 3A) . Overall numbers of cells and the cell size distribution and intensity distribution of the neuronal marker UCHL1 were highly similar, indicating comparability among the genotypes (Fig.  3B ). Using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), we confirmed that Hrt4 transcript abundance was reduced in sensory ganglia of Na v 1.7 −/− mice and not Na v 1.8 −/− mice (Fig. 3C ), which is consistent with the microarray data by Minett et al. (15) .
To test for functional cellular changes associated with the absence of Na v 1.7 and reduced expression of the gene encoding 5-HT 4 for PKA-II signaling, we compared the responses of sensory neurons isolated from wild-type Na v 1.7 +/+ and Na v 1.7 −/− mice using the pRII assay. We tested the response to different GPCR ligands (5-HT and PGI 2 ), to the adenylyl cyclase activator Fsk, and to the cell-permeable cAMP analog Sp-8-Br-cAMPS-AM (8-bromoadenosine-3′,5′-cyclic monophosphorothioate, Sp-isomer, and acetoxymethyl ester). Costaining for pRII and RIIb revealed that Na v 1.7 deficiency results in reduced numbers of cells that respond to 5-HT (Fig. 3D) . Consistent with the reduced Hrt4 transcript abundance leading to less receptor, the maximum amplitude but not the EC 50 of the pRII response to 5-HT was reduced in sensory neurons of Na v 1.7 −/− mice (Fig. 3E) . pRII responses to PGI 2 , Fsk, or Sp-8-Br-cAMPS-AM were the same in cultures from the Na v 1.7 +/+ and Na v 1.7 −/− mice (Fig. 3E ).
The similarity in the dose responses of the downstream activators Fsk and Sp-8-Br-cAMPS-AM between Na v 1.7 +/+ and Na v 1.7 −/− mice (Fig. 3G ) indicated that the reduction in response to 5-HT resulted from a change at the receptor level and not from downstream effectors such as adenylyl cyclases. The similarity in the responses of neurons to PGI 2 in both genotypes indicated that the general ability to signal through Ga s -coupled GPCRs was not impaired but that the reduced pRII ). (K and L) Effect of naltrexone and CTOP on the inhibition of the 5-HT-induced pRII signal by DAMGO. In (B) to (L), concentrations are indicated in micromolar; control conditions were treated with solvent; data are presented as means ± SEM; n = 3 to 4 independent experiments; >2000 neurons per condition; two-way analysis of variance (ANOVA) with Bonferroni's test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 indicate significance levels between baseline and stimulated conditions; § P < 0.05, § § P < 0.01, § § § P < 0.001 indicate significance levels between stimulated and inhibited conditions. response was specific for 5-HT stimulation of 5-HT 4 receptors (Fig.  3G ). These data confirmed that sensory neurons from animals deficient in either of these two voltage-gated Na + channels were functional with regard to their ability to activate PKA signaling and that only mice deficient for Na v 1.7 exhibited reduced Hrt4.
RIIb is less abundant in dorsal root ganglia from Na v 1.7
−/− mice The pRII dose-response data presented in Fig. 3E were normalized. However, analysis of the non-normalized data as presented in the kinetic experiments revealed an additional reduction of pRII baseline intensity values by 8% in Na v 1.7 −/− mice compared to wild-type litters (Fig. 4A , Ctrl). This was unexpected because the baseline activity of PKA-II is commonly tightly controlled and maintained at a constant level (28, 29) . Thus, the observed reduction in baseline activity indicates that Na v 1.7 deficiency resulted in another change that could affect intracellular signaling. Similar to the reduction in 5-HT 4 receptors, this effect on the basal amount of pRII was specific for Na v 1.7 −/− mice and not present in Na v 1.8 −/− mice (Fig. 4B , Ctrl). A reduced pRII signal could be the result of the identified down-regulation of 5-HT 4 -mediated input. However, we observed that the phosphorylation signals in response to Fsk were also lower than those in wild type (Fig. 4A, Fsk) . This effect was specific to Na v 1.7
−/− mice because we did not detect this reduction in pRII intensity in Na v 1.8 −/− mice (Fig. 4B, Fsk) . The reduction in the amount of pRII could result from reduced abundance of total RII due to reduced gene expression or increased degradation or could result from reduced phosphorylation. Therefore, we analyzed for the abundance of RIIb, the major PKA-RII regulatory subunit in rat nociceptive neurons (19) . As in rats, we also found that in mice, RIIb was enriched in small-to medium-sized sensory neurons (Fig. 4C) . Na v 1.7 deficiency did not affect the number of RIIb(+) neurons but resulted in a general shift toward lower RIIb intensities (Fig. 4, C and D) . The mean RIIb intensity was 11% lower in RIIb(+) neurons of Na v 1.7
−/− mice compared to that in neurons from wild-type litters (Fig. 4E ). These data indicate that the 5-HT pronociceptive input and the mediating intracellular signaling component RIIb are reduced in Na v 1.
Opioid signaling is amplified in Na v 1.7 −/− mice We next investigated the effect of Na v 1.7 or Na v 1.8 deficiency on the cellular activity of the antinociceptive opioid receptor signaling system using the nonspecific opioid receptor agonist fentanyl and the nonspecific antagonist naltrexone. Neither fentanyl nor naltrexone altered the baseline amount of pRII in neurons from Na v 1.7 −/− or Na v 1.8 −/− mice (Fig. 4, A and B, Fent and NTX). These results are consistent with those we obtained from wild-type rat pain-sensing neurons (Fig. 1, F and G) . The absence of an effect of naltrexone indicated that there is no basal opioid receptor activity in the neurons from Na v 1.7 −/− mice or wild-type rat pain-sensing neurons. The lack of an effect of fentanyl indicated that the basal adenylyl cyclase activity and thus PKA activity and pRII abundance were low in cells under basal conditions and that the activation of the opioid receptor did not further suppress this pathway.
Next, we tested the effect of fentanyl and naltrexone on changes of pRII intensity induced by 5-HT. The Na v 1.7 −/− mice have increased production of endogenous opioids (15) , which would be expected to result in opioid receptor desensitization due to prolonged opioid exposure (30) . However, we found that the inhibition of the 5-HT-induced pRII intensity by fentanyl was greater in sensory neurons of Na v 1.7 −/− mice compared with the inhibitory effect in neurons from the wild-type mice ( To analyze how these differences in responses distributed over subgroups of sensory neurons, we plotted the pRII intensities of all analyzed neurons versus their size and applied fixed intensity and size thresholds Values are means ± SEM; n = 4 independent experiments; >8000 neurons per condition; two-way ANOVA with Bonferroni's test; ****P < 0.0001.
to evaluate the number of responding neurons (Fig. 4F) . We compared the percentage of small-sized sensory neurons that exceeded the threshold for pRII intensity of neurons from wild-type and Na v 1.7
−/− mice. We compared the population size under control conditions, in response to individual exposure to pro-or antinociceptive agonists and to their combination. Stimulation with 5-HT increased pRII signals in 17% of smaller-sized sensory neurons from Na v 1.7 −/− mice and in 21% from wild-type mice. Simultaneous application of fentanyl reduced the number of 5-HT-responsive neurons from 17 to 6% in Na v 1.7 −/− (Fig. 4F , red arrow) and from 21 to 17% in wild types (Fig. 4F, 5-HT/Fent) . Thus, the signaling amplitude (Fig. 4A ) and the number of cells responding to 5-HT in the presence of fentanyl were reduced in Na v 1.7 −/− animals (Fig. 4F) .
Coincident activation of stimulatory and inhibitory GPCRs is considered to augment the sensitivity, amplitude, and duration of G i signaling by a mechanism involving cAMP-dependent interaction of RII subunits with Ga i proteins (31) . Thus, a reduced 5-HT pronociceptive input should result in a reduced antinociceptive opioid input. The relative opioid inhibition should remain the same.
We compared the pRII response of neurons from wild-type or Na v 1.7 −/− mice exposed to a single concentration of 5-HT and increasing concentrations of fentanyl to determine how the reduced 5-HT-mediated ) with fentanyl (Fen, 2 mM), naltrexone (NTX, 10 mM), serotonin (5-HT, 0.2 mM), combinations thereof, or Fsk (10 mM). Basal pRII intensity was 8% lower in sensory neurons from Nav1.7 −/− mice (genotype effect in Ctrl: F 1,36 = 22.9, n = 4, P < 3 × 10
−05
). The inhibitory effect of fentanyl was greater in sensory neurons of Nav1.7 −/− mice (F 1,35 = 37, n = 4, P < 6 × 10 ; >3000 neurons per condition; two-way ANOVA with Bonferroni' s test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
pronociceptive input affected the dose-response relationship for fentanyl (Fig. 5, A and B) . The IC 50 values (16 nM for Na v 1.7 −/− neurons and 36 nM for wild-type neurons) were not significantly different between the two genotypes, suggesting a similar receptor-ligand affinity. Nevertheless, the response amplitude of fentanyl over the entire dose-response curve was shifted to lower amplitudes in the Na v 1.7 −/− neurons (Fig. 5A ). This shift was unexpected if the G i response scales with the G s input, as has been reported (31). This effect was attributed not only to neurons from the Na v 1.7-deficient mice responding less to 5-HT but also to the relative effect of fentanyl on 5-HT-responding neurons being higher in neurons from Na v 1.7-deficient animals, indicating increased effectiveness of the opioid-mediated signal ( fig. S3A) . At the single-cell level, the opioid response was shown to be a specific effect of the 5-HT-responding RIIb(+) neurons (Fig. 5B ). In addition, this effect was caused by fewer cells reacting and a larger percentage of responding cells being inhibited by fentanyl ( fig. S3B ). We obtained similar results with DAMGO: The IC 50 value that would inhibit 5-HT-induced pRII was similar, but the maximum response was greater in neurons from the Na v 1.7 −/− mice ( fig. S3, E and F) .
To determine whether the enhanced effectiveness of opioid signaling in the absence of Na v 1.7 was independent of the pRII-inducing receptor stimulus, we applied increasing doses of fentanyl in the presence of Fsk.
The effectiveness of fentanyl was significantly enhanced in Na v 1.7-deficient neurons (Fig. 5C and fig. S3C ). Consistent with the observed reduction in basal RIIb and pRII signal (Fig. 4) , single-cell analysis showed that the number of Fsk-stimulated neurons was significantly less in the Na v 1.7-deficient mice in the absence of fentanyl (Fig. 5D) . Fentanyl reduced the population of responding cells by 39% in Na v 1.7 +/+ mice (28% at 0 mM to 17% at 2 mM fentanyl) and by 61% in Na v 1.7 −/− mice (23% at 0 mM to 9% at 2 mM fentanyl) (Fig. 5D  and fig. S3D ). The increased inhibition of Fsk-responsive neurons by fentanyl in Na v 1.7-deficient neurons remained significant even after normalization to remove the effect of basal differences in the number of Fsk-responsive neurons ( fig. S3D) . Thus, the relative and absolute reduction by opioids of the pRII signal and the responding cell number was substantially enhanced in Na v 1.7
Synergistic dampening of pain signaling renders opioids more effective in reducing sodium currents One functional consequence of PKA signaling in pain-sensing neurons is enhanced activity of the Na v 1.8 channel and increased Na v 1.8-mediated current (32, 33) . To determine whether the shift in the balance of pro-and antinociceptive signaling efficiency (reduced and increased, respectively) altered the ability of opioids to suppress TTXr sodium currents, we performed voltage-clamp analysis of in vitro cultured sensory neurons from wild-type and Na v 1.7 −/− mice and measured TTXr sodium currents in the presence and absence of fentanyl (Fig. 6) . After normalizing the baseline currents, we found that fentanyl produced a greater reduction in Na v 1.8 TTXr currents in the cells from the Na v 1.7 −/− mice (Fig. 6, B and C) . These results are consistent with the cellular studies showing that opioid signaling was more effective at reducing PKA activity in Na v 1.7 −/− mice (Fig. 5 ). This enhanced opioid-mediated reduction in sodium current would make the neurons less active, which suggests that the altered pro-and antinociceptive signaling that we observed likely contributes to the analgesic phenotype of mouse and human Na v 1.7 −/− mutants. In conclusion, our data indicate that the absence of Na v 1.7 results in significantly reduced 5-HT pronociceptive input, with a concomitant reduction of the intracellular mediator RIIb and the abundance of pRII. Concomitant with the reduction in pronociceptive signaling, antinociceptive input and signaling effectiveness were enhanced, resulting in a synergistic reduction in pain sensitivity and neuronal sodium current activity. Because these synergistic changes occurred specifically in the absence of Na v 1.7, but not of Na v 1.8, the balance of pronociceptive versus antinociceptive signaling is controlled specifically by Na v 1.7.
DISCUSSION
Genetic loss of function of Na v 1.7 causes congenital insensitivity to pain in mice and humans (9, 11, 34) , yet acute block of Na v 1.7 with potent and selective Na v 1.7 antagonists does not (14) . This contradiction could be resolved if Na v 1.7 not only contributes acutely to electrical activity but also regulates other cellular processes measurable after prolonged times of channel inhibition and/or by readout parameters other than acute analgesia. Beyond changes of acute electrical activity, Minett et al. found in the spinal cord of Na v 1.7 −/− mice that substance P release is also abolished and opioid activity is tonically increased (10, 15) . Both observations, nevertheless, may be the direct consequence of reduced depolarization and thereby reduced depolarization-induced secretion of vesicles containing substance P or opioid or both kinds of secretory vesicles. In contrast, here, we showed that animals lacking Na V 1.7 have alterations beyond the acute depolarization event. We found the loss of functional Na V 1.7 to result in altered pro-and antinociceptive GPCR signaling within sensory neurons even in the neutral environment of cell culture medium (Fig. 7) .
Our results highlight the intimate interaction between pro-and antinociceptive inputs. 5-HT has been described to counter the effects of opioids on the system level. For example, agonists of 5-HT 4 receptors are used to counteract constipation resulting from chronic opioid use (35, 36) and to counteract opioid-induced respiratory depression (37) . At the level of neuronal circuits, 5-HT reuptake inhibitors counteract afferent pain input by increasing the activity of descending inhibitory neurons in the spinal cord (38, 39) . Our results further support this antagonistic role: We found that 5-HT 4 receptor signaling and opioid signaling were functionally connected at the single-cell level in a subgroup of peripheral nociceptive neurons.
The balance between pro-and antinociceptive input scales with stimulus intensity. Thus, increased pronociceptive input results in a C B A Na V 1.7 +/+ 100 nM fentanyl Na V 1.7 -/-100 nM fentanyl Na V 1.7 +/+ Na V 1.7 -/-B a s e l i n e F e n t a n y l B a s e l i n e F e n t a n y l N a 1 . 
An tin oc ice pti ve inp ut
Pro noc icep tive inpu t Fig. 7 . Synergistic regulation of pro-and antinociceptive signaling in Na v 1.7-deficient mice. Nav1.7 deficiency results in a reduction in 5-HT 4 receptors, due to decreased gene expression, and the RIIb subunit (and, presumably, also the catalytic subunit) of PKA. Thereby, the pronociceptive input in sensory neurons (red) is strongly reduced. Simultaneously, the antinociceptive input (green) is increased owing to enhanced opioid receptor activity and increased expression of the gene encoding the precursor of endogenous opioid peptides (enkephalins). This synergistic regulation shifts the balance toward antinociceptive signaling and thus contributes to the painfree phenotype in Na v 1.7-deficient mice.
concomitant increase in the counterbalancing opioid antinociceptive signal to maintain a constant net response (31) . Our results indicate that, without Na v 1.7, this scaling does not occur (Fig. 7) . We found that the reduction of the pronociceptive serotonergic input in Na v 1.7 −/− is not followed by a corresponding reduction of the opioid input. On the contrary, the effectiveness of opioid signaling was significantly increased, resulting in stronger inhibition of pRII and suppression of TTXr sodium currents. Whereas about 50% of the serotonin-induced pRII pronociceptive signaling remained even after maximal doses of opioid treatment in neurons from wild-type animals, the serotonininduced pRII pronociceptive signal was nearly completely abolished by maximal doses of opioids in Na v 1.7 −/− neurons (Fig. 5, A and B  and fig. S3, A and B) . This increased efficacy could be of importance in respect to the only moderate effectiveness of opioids in patients, which is at 10 to 15% on average (3) (4) (5) . Thus, it will be of importance to test whether a pharmacological block of Na v 1.7 results in a similar increase in the cellular efficacy of opioids and whether this also translates into increased pain reduction that exceeds the currently observed average of 10 to 15% pain relief in patients. Even further, desensitization to prolonged presence of opioids is the net result of opioid receptor internalization, receptor uncoupling, and the upscaling of the counteracting pronociceptive signaling that we identified here. Thus, it will be of interest to detail if and how the lack of Na v 1.7 and the observed lack of scaling results in reduced opioid induced desensitization (8) . It will be especially interesting to test whether pharmacological inhibitors of Na v 1.7 result in a similar reduction of the scaling effect, which might have been missed in studies solely evaluating for acute Na v 1.7 inhibitor-induced analgesia. A report about the increased effectiveness of opioids by combining them with the blocker of voltage-gated sodium channels including Na v 1.7, lidocaine, could indicate such a pharmacologically induced synergism (40) .
PENK mRNA is up-regulated in the complete absence of Na v 1.7 activity but not after partial blockade (15) . However, some GPCRs are also rapidly modulated by nontranscriptional changes that are initiated by changes in intracellular sodium concentration. Increased intracellular sodium concentration affects GPCR ligand binding and allosteric regulation of biased signaling. In particular, increased intracellular sodium uncouples opioid receptors from Ga i and increases the constitutive signaling activity through the b-arrestin pathway (41) (42) (43) (44) . A reduction in the intracellular concentration of sodium could explain the observed increased Ga i signaling activity resulting in the enhanced reduction of PKA activity. However, the specificity of our observations to Na v 1.7 −/− but not to Na v 1.8 −/− mice, which still have remaining nociceptive neuron activity and pain reception (20) , argues against large changes in intracellular sodium concentration as the cause of the increase in opioid receptor signaling efficacy. Still, another possibility is that Na v 1.7 and opioid receptors could be colocalized in signaling hubs that enable local changes in sodium concentration to influence opioid receptor activity. Future work is needed to detail the mechanism leading to the synergistic changes that dampen pain signaling.
The loss of function of Na v 1.7 appears to cause long-term changes to intracellular nociceptive signaling, and we found that these changes were present even in the absence of exogenously added opioids, which may indicate that the continuous presence of opioids is unnecessary to maintain the altered signaling state. Our finding of reduced pronociceptive input and increased effectiveness of antinociceptive opioids provides evidence that sustained dampening of the intracellular pain signaling in nociceptive neurons can be achieved, at least in the absence of Na v 1.7. Our results indicated that Na v 1.7 may regulate the homeostatic set point of pain signaling, which agrees with previous reports of the close link of the expression of the gene encoding Na v 1.7, its abundance, and pain (15, 31, 45, 46) . We propose that our assay, which monitors pro-and antinociceptive signaling as well as RIIb abundance in one single readout, can be used to identify potential drug candidates that shift the balance of these in favor of antinociceptive signaling. Current inhibitors of Na v 1.7 activity lack direct analgesic activity on their own. However, our data suggest the possibility that some pain conditions will benefit from opioid treatment combined with inhibition of Na v 1.7, which could prolong and enhance opioid effectiveness, thereby offering better pain management.
MATERIALS AND METHODS

Antibodies
The following antibodies were used in this study: chicken polyclonal antibodies against UCHL1 ( 
Animals
Male Sprague-Dawley rats (200 to 225 g, aged 8 to 10 weeks) were obtained from Harlan Laboratories. Conditional Na v 1.7 knockout mice were generated by crossing floxed (SCN9A) Na v 1.7 mice with AdvillinCre mice (10, 34) , and global Nav1.8 knockout mice were used (20) . Female and male mice were between 6 and 20 weeks of age. Mice and rats were kept on a 12-hour light/dark cycle and provided with food and water ad libitum. All animal experiments were performed in accordance with the German animal welfare law and approved by the Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen or approved by the U.K. Home Office according to guidelines set by personal and project licenses, as well as guidelines of the Committee for Research and Ethical Issues of IASP. Animals were sacrificed between 9 and 12 a.m. by CO 2 intoxication. Dorsal root ganglia from rats (L1 to L6) or mice (lumbar and thoracic) were removed within 30 min per animal.
Dorsal root ganglion neuron cultures
Dorsal root ganglia were desheathed, pooled, and incubated in Neurobasal A/B27 medium (Invitrogen) containing collagenase P (Roche) (0.2 U/ml, 1 hour, 37°C, 5% CO 2 ). The dorsal root ganglia were dissociated by trituration with fire-polished Pasteur pipettes. Axon stumps and disrupted cells were removed by bovine serum albumin (BSA) gradient centrifugation (15% BSA, 120g, 8 min). Viable cells were resuspended in Neurobasal A/B27 medium, plated in poly-L-ornithine (0.1 mg/ml)/laminin (5 mg/ml)-precoated 96-well imaging plates (Greiner), and incubated overnight (37°C, 5% CO 2 ). Neuron density was 1500 neurons/cm 2 .
Stimulation of dorsal root ganglion neurons Dorsal root ganglion neurons were stimulated 24 hours after isolation in 96-well imaging plates. Compounds were dissolved in 12.5 ml of PBS (pH 7.4) in 96-well V-bottom plates, mixed with 50 ml of medium from the culture wells, and added back to the same wells. Stimulations were performed with automated eight-channel pipettes (Eppendorf) at low dispense speed on heated blocks, and stimulated cells were placed back in the incubator. The cells were fixed for 10 min at room temperature (RT) by adding 100 ml of 8% paraformaldehyde, resulting in a final concentration of 4%.
Immunofluorescence staining Fixed cells were treated with goat serum blocking solution (2% goat serum, 1% BSA, 0.1% Triton X-100, and 0.05% Tween 20 for 1 hour at RT) and incubated with respective primary antibodies diluted in 1% BSA in PBS (pH 7.4) at 4°C overnight. After three washes with PBS (30 min, RT), cells were incubated with secondary Alexa dye-coupled antibodies (1:1000; 1 hour, RT). After three final washes (30 min, RT), wells of 96-well plates were filled with PBS, sealed, and stored at 4°C until scanning.
Quantitative microscopy
Stained dorsal root ganglion cultures in 96-well plates were scanned using the Cellomics ArrayScan XTI with a light-emitting diode light source. Images of 1024 × 1024 pixels were acquired with a 10× objective and analyzed using the Cellomics software package. Briefly, images of UCHL1 staining were background-corrected (low-pass filtration), converted to binary image masks (fixed threshold), and segmented (geometric method), and neurons were identified by the following: object selection parameter size, 80 to 7500 mm 2 ; circularity (perimeter 2 /4p area), 1 to 3; length-to-width ratio, 1 to 2; average intensity, 800 to 12,000; and total intensity, 2 × 10 5 to 5 × 10 7 . These image masks were then overlaid on images obtained at other fluorescence wavelengths to quantify signal intensities. To calculate spillover between fluorescence channels, three respective controls were prepared for each triple staining: (i) UCHL1 alone, (ii) UCHL1 + antibody 1, and (iii) UCHL1 + antibody 2. Raw fluorescence data of the controls were used to calculate the slope of best-fit straight lines by linear regression, which was then used to compensate for spillover, as described previously (47) . Compensated data were scaled to a mean value of 1 (or 1000) for the unstimulated cells to adjust for variability between experimental days. One-and twodimensional probability density plots were generated using R packages (48) . Gating of subpopulations was performed by setting thresholds at local minima of probability density plots. The mean number of analyzed neurons was 31,288 ± 3231 (L1 to L6 only) per rat and 30,965 ± 1438 per mouse (lumbar and thoracic dorsal root ganglion).
Electrophysiology
All electrophysiological recordings were performed using an Axopatch 200B amplifier and a Digidata 1440A digitizer (Axon Instruments), controlled by Clampex software (version 10, Molecular Devices). Filamented borosilicate microelectrodes (GC150TF-7.5, Harvard Apparatus) were coated with beeswax and fire-polished using a microforge (Narishige) to give resistances of 2 to 3 megohms. For voltage-clamp experiments, the following solutions were used. The extracellular solution contains 70 mM NaCl, 70 mM choline chloride, 3 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 20 mM tetraethylammonium chloride, 0.1 mM CdCl 2 , 0.3 mM TTX, 10 mM Hepes, and 10 mM glucose (pH 7.3) with NaOH. The intracellular solution contains 140 mM CsF, 1 mM EGTA, 10 mM NaCl, and 10 mM Hepes (pH 7.3) with CsOH. Unless otherwise stated, standard whole-cell currents were acquired at 25 kHz and filtered at 10 kHz (low-pass Bessel filter). After achieving whole-cell configuration, the cell was left for 5 min to dialyze the intracellular solution. A holding potential of −100 mV was applied, and series resistance was compensated by ≥70%. All currents were leak-subtracted using a p/4 protocol. To record TTXr sodium currents, we applied a depolarizing voltage-pulse protocol to the cell; the cell was held at −100 mV and then stepped to −15 mV for 50 ms before returning back to −100 mV. This step was applied every 5 s for the duration of the experiment. The cells were continuously perfused using a gravity-fed perfusion system. All electrophysiological data were extracted using Clampfit (version 10, Molecular Devices) and analyzed using GraphPad Prism software (version 6, GraphPad).
Statistical analysis
Statistical analyses were performed with Student's t tests, one-way ANOVA, or two-way ANOVA with respective post hoc tests, as indicated in the figure legends. P < 0.05 was considered statistically significant. Dose-response curves from HCS microscopy were generated using nonlinear regression curve-fitting (three parameters, standard Hill slope) with Prism (GraphPad). The parameters of the model (top, bottom, or pEC 50 /pIC 50 values) were compared using the extra-sum-of-squares F test. HCS kinetic experiments were analyzed with R (48) using ordinary two-way ANOVA. Bonferroni's post hoc analysis was applied to determine P values of selected pairs defined in a contrast matrix using the R library multcomp. Error bars represent the SEM of three to five independent replicate experiments using cells of different animals.
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